文献速递儿科影像腹部US

英夫利昔单抗及英夫利昔单抗-硫唑嘌呤联合治疗初诊儿童小肠克罗恩病的超声纵向自然史定义

Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy.
PubMed 文献 · Pediatr Radiol · 2017-04-18

纳入28例初诊回肠克罗恩病接受英夫利昔单抗治疗的儿童,在基线和治疗后约2周、1个月、3个月、6个月行肠道超声。结果显示病变长度、最大肠壁厚度、肠壁和肠系膜彩色多普勒信号在治疗后约2周即较基线下降,所有实验室炎症标志物在1个月时下降;肠壁彩色多普勒信号与粪便钙卫蛋白强相关(ρ=0.710)。

要点

  • 英夫利昔单抗治疗后约2周,肠壁彩色多普勒信号即较基线下降(1.7±0.9 vs. 1.2±0.8,P=0.002)。
  • 肠壁彩色多普勒信号与粪便钙卫蛋白强相关(ρ=0.710;P<0.0001)。
  • 最大肠壁厚度、病变长度和肠壁彩色多普勒信号随时间变化,校正年龄、性别、硫唑嘌呤治疗、扫描放射科医师和基线简短儿童克罗恩病活动指数评分后仍显著。

核心结论

  • 肠道超声表现最早在英夫利昔单抗治疗开始后2周即发生变化;肠壁彩色多普勒信号与粪便钙卫蛋白强相关。

研究设计与样本

  • 纳入28例初诊回肠克罗恩病接受英夫利昔单抗治疗的儿童,在医学治疗前及治疗开始后约2周、1个月、3个月和6个月行肠道超声,并在基线、1个月和6个月行实验室检查;采用线性混合模型比较各次访视的平均结果并评估超声测量是否随时间变化,采用Spearman秩相关评估双变量关系。

关键影像表现/征象

  • 与基线相比,英夫利昔单抗开始后约2周病变累及长度下降(12.0±5.4 vs. 9.1±5.3 cm,P=0.02)。
  • 与基线相比,英夫利昔单抗开始后约2周最大肠壁厚度下降(5.6±1.8 vs. 4.7±1.7 mm,P=0.02)。
  • 与基线相比,英夫利昔单抗开始后约2周肠壁彩色多普勒信号下降(1.7±0.9 vs. 1.2±0.8,P=0.002)。
  • 与基线相比,英夫利昔单抗开始后约2周肠系膜彩色多普勒信号下降(1.1±0.9 vs. 0.6±0.6,P=0.005)。

诊断标准与关键数值

  • 肠壁彩色多普勒信号与粪便钙卫蛋白强相关(ρ=0.710;P<0.0001)。
  • 线性混合模型证实,校正年龄、性别、硫唑嘌呤治疗、扫描放射科医师和基线简短儿童克罗恩病活动指数评分后,最大肠壁厚度(P=0.04)、病变累及长度(P=0.0002)和肠壁彩色多普勒信号(P<0.0001)随英夫利昔单抗治疗随时间变化。
  • 所有实验室炎症标志物在1个月时下降(P值<0.0001)。

临床应用与阅片要点

  • 在初诊儿童小肠克罗恩病接受英夫利昔单抗治疗后的随访中,肠道超声可观察到病变长度、最大肠壁厚度、肠壁和肠系膜彩色多普勒信号在约2周时较基线下降。
  • 肠壁彩色多普勒信号与粪便钙卫蛋白强相关(ρ=0.710;P<0.0001),可作为评估炎症活动的超声指标之一。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Little is known about changes in the imaging appearances of the bowel and mesentery over time in either pediatric or adult patients with newly diagnosed small bowel Crohn disease treated with anti-tumor necrosis factor-alpha (anti-TNF-α) therapy.

OBJECTIVE: To define how bowel ultrasound findings change over time and correlate with laboratory inflammatory markers in children who have been newly diagnosed with pediatric small bowel Crohn disease and treated with infliximab.

MATERIALS AND METHODS: We included 28 pediatric patients treated with infliximab for newly diagnosed ileal Crohn disease who underwent bowel sonography prior to medical therapy and at approximately 2 weeks, 1 month, 3 months and 6 months after treatment initiation; these patients also had laboratory testing at baseline, 1 month and 6 months. We used linear mixed models to compare mean results between visits and evaluate whether ultrasound measurements changed over time. We used Spearman rank correlation to assess bivariate relationships.

RESULTS: Mean subject age was 15.3±2.2 years; 11 subjects were girls (39%). We observed decreases in mean length of disease involvement (12.0±5.4 vs. 9.1±5.3 cm, P=0.02), maximum bowel wall thickness (5.6±1.8 vs. 4.7±1.7 mm, P=0.02), bowel wall color Doppler signal (1.7±0.9 vs. 1.2±0.8, P=0.002) and mesenteric color Doppler signal (1.1±0.9 vs. 0.6±0.6, P=0.005) at approximately 2 weeks following the initiation of infliximab compared to baseline. All laboratory inflammatory markers decreased at 1 month (P-values<0.0001). There was strong correlation between bowel wall color Doppler signal and fecal calprotectin (ρ=0.710; P<0.0001). Linear mixed models confirmed that maximum bowel wall thickness (P=0.04), length of disease involvement (P=0.0002) and bowel wall color Doppler signal (P<0.0001) change over time in response to infliximab, when adjusted for age, sex, azathioprine therapy, scanning radiologist and baseline short pediatric Crohn's disease activity index score.

CONCLUSION: The ultrasound appearance of the bowel changes as early as 2 weeks after the initiation of infliximab therapy. There is strong correlation between bowel wall color Doppler signal and fecal calprotectin.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Dillman JR, Dehkordy SF, Smith EA, et al. Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy. Pediatr Radiol. 2017. PMID: 28421251. doi:10.1007/s00247-017-3848-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。